Frontiers in medicine
Screening for inflammation and treatment with colchicine in adults with known cardiovascular disease: an analysis of 13.5 million patients
By Mainous AG, Yin L and Orlando FA.
Abstract
Background
Identifying and treating inflammation is a recommended atherosclerotic cardiovascular disease (ASCVD) prevention strategy. The practice of screening for and treating inflammation is unknown. This study examined screening for inflammation and treatment with colchicine among patients with established ASCVD.
Methods
Using the Epic COSMOS electronic health record (EHR) database, we compared adults with known ASCVD between two time frames: (1) 2023 (colchicine FDA approved for ASCVD prevention) until April 2026 and (2) September 2025 [American College of Cardiology (ACC) scientific statement released] until April 2026. We examined screening for inflammation and treatment of inflammation. Chi-square tests compared differences before and after the ACC scientific statement on inflammation.
